Budesonide Once-daily Pill Now Available in US for Crohn’s Disease

Budesonide Once-daily Pill Now Available in US for Crohn’s Disease
Ferring Pharmaceuticals has announced the launch of Ortikos (budesonide), the first and only once-daily pill treatment for people, 8 and older, with mild to moderate Crohn’s disease, in the U.S. With Ortikos, budesonide is now available in 9 and 6 mg extended-release capsules, the recommended total daily dosages for the induction and maintenance of remission of mild to moderate Crohn’s disease involving the ileum (the final section of the small intestine) and/or the initial part of the colon. Healthcare providers can check with their local pharmacies if Ortikos is in stock. Patients may pay the discounted rate of $10 for a 30-day supply through Ferring’s copay savings card. “Patients with Crohn’s disease are seeking not only safe and efficacious treatments that can provide incremental improvement, but also convenient options when managing this chronic condition,” Miguel Regueiro, MD, of the Cleveland Clinic, said in a press release. “The availability of Ortikos addresses the needs of patients, helping to treat and maintain clinical remission with one pill per day,” he added. The recommended dosage of budesonide extended-release capsules — such as Ortikos and Entocort EC — for treatment initiation is 9 mg once daily for up to eight weeks in individuals age 8 or older, followed by 6 mg once-a-day for two weeks in pediatric patients. For maintenance of clinical remission in adults, 6 mg daily up to three months is the recommended dosage. Entocort EC (sold by Perrigo) is only available in 3 mg capsules, thus requiring two to three capsules to achieve the recommended dosage. Ortikos, originally developed by Sun Pharmaceutical, requires a single pill per day. Approved in July 2019, Ortikos’ safety and effectiveness were based on c
Subscribe or to access all post and page content.